The value of ultrasound guided laser ablation in papillary thyroid recurrence carcinoma: A retrospective, single center study from China
ObjectiveThe efficacy and safety of ultrasound-guided percutaneous laser ablation (PLA) for treating recurrent papillary thyroid cancer nodules (RPTCNs).MethodsA retrospective study was conducted in 43 patients with single recurrent thyroid cancer which was diagnosed by fine needle aspiration biopsy...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.946966/full |
| _version_ | 1811274414117879808 |
|---|---|
| author | Liang Yong-ping Zhang Juan Jing-wu Li Huai-hua Qi Jing-ping Liu Yong-feng Zhao Wen-gang Liu Xing-hao Zhang Ping Zhou |
| author_facet | Liang Yong-ping Zhang Juan Jing-wu Li Huai-hua Qi Jing-ping Liu Yong-feng Zhao Wen-gang Liu Xing-hao Zhang Ping Zhou |
| author_sort | Liang Yong-ping |
| collection | DOAJ |
| description | ObjectiveThe efficacy and safety of ultrasound-guided percutaneous laser ablation (PLA) for treating recurrent papillary thyroid cancer nodules (RPTCNs).MethodsA retrospective study was conducted in 43 patients with single recurrent thyroid cancer which was diagnosed by fine needle aspiration biopsy (FNAB). The extent of ablation was assessed by contrast-enhanced ultrasound (CEUS) 24h after PLA. At baseline (before ablation), 6, and 12 months, and every 6 months thereafter, the following were recorded: nodule maximum diameter, volume reduction rate (VRR), complications, and side effects.ResultAll 43 patients were successfully treated with PLA without serious complications. All patients underwent CEUS 24 hours after PLA treatment, and all achieved complete ablation. The success rate of single ablation was 100%. The average follow-up time was 23.47 ± 6.50 months, 12 ~ 36 months. At the last follow-up, 32 (74.4%) ablation lesions disappeared completely and 11 (25.6%) ablation lesions showed scar-like changes. No lymph node metastasis was found during follow-up. The maximum diameter and volume of nodules decreased from 5.1 ± 1.4 mm, 86.22 ± 20.46 mm3 before operation to 0.73 ± 1.1 mm, 1.02 ± 1.92 mm3 at the end of observation (P < 0.01). The average volume reduction rates (VRR) at 6, 12, 18, 24, 30 and 36 months after ablation were 11.92%, 60.64%, 82.26%, 90.96%, 93.7% and 97.79% respectively. No regrowth of treated nodule and distant metastases were detected. One patient (2.3%) had local recurrence and was treated with PLA again.ConclusionUltrasound-guided PLA appears to be effective and safe for treating unifocal RPTCNs in selected patients who are ineligible for surgery, which is suitable for clinical application and promotion. |
| first_indexed | 2024-04-12T23:18:28Z |
| format | Article |
| id | doaj.art-90403ee03cc046ff88bfecbebcc86005 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-12T23:18:28Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-90403ee03cc046ff88bfecbebcc860052022-12-22T03:12:35ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-09-011310.3389/fendo.2022.946966946966The value of ultrasound guided laser ablation in papillary thyroid recurrence carcinoma: A retrospective, single center study from ChinaLiang Yong-ping0Zhang Juan1Jing-wu Li2Huai-hua Qi3Jing-ping Liu4Yong-feng Zhao5Wen-gang Liu6Xing-hao Zhang7Ping Zhou8Department of Ultrasound, Tangshan People’s Hospital, North China University of Science and Technology, Tang Shan, ChinaDepartment of Breast Surgery, Tangshan People’s Hospital, North China University of Science and Technology, Tang Shan, ChinaDepartment of Breast Surgery, Tangshan People’s Hospital, North China University of Science and Technology, Tang Shan, ChinaDepartment of Breast Surgery, Tangshan People’s Hospital, North China University of Science and Technology, Tang Shan, ChinaDepartment of Ultrasound, Tangshan People’s Hospital, North China University of Science and Technology, Tang Shan, ChinaDepartment of Ultrasound, The Third Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Ultrasound, The Third Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Ultrasound, The Third Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Ultrasound, The Third Xiangya Hospital, Central South University, Changsha, ChinaObjectiveThe efficacy and safety of ultrasound-guided percutaneous laser ablation (PLA) for treating recurrent papillary thyroid cancer nodules (RPTCNs).MethodsA retrospective study was conducted in 43 patients with single recurrent thyroid cancer which was diagnosed by fine needle aspiration biopsy (FNAB). The extent of ablation was assessed by contrast-enhanced ultrasound (CEUS) 24h after PLA. At baseline (before ablation), 6, and 12 months, and every 6 months thereafter, the following were recorded: nodule maximum diameter, volume reduction rate (VRR), complications, and side effects.ResultAll 43 patients were successfully treated with PLA without serious complications. All patients underwent CEUS 24 hours after PLA treatment, and all achieved complete ablation. The success rate of single ablation was 100%. The average follow-up time was 23.47 ± 6.50 months, 12 ~ 36 months. At the last follow-up, 32 (74.4%) ablation lesions disappeared completely and 11 (25.6%) ablation lesions showed scar-like changes. No lymph node metastasis was found during follow-up. The maximum diameter and volume of nodules decreased from 5.1 ± 1.4 mm, 86.22 ± 20.46 mm3 before operation to 0.73 ± 1.1 mm, 1.02 ± 1.92 mm3 at the end of observation (P < 0.01). The average volume reduction rates (VRR) at 6, 12, 18, 24, 30 and 36 months after ablation were 11.92%, 60.64%, 82.26%, 90.96%, 93.7% and 97.79% respectively. No regrowth of treated nodule and distant metastases were detected. One patient (2.3%) had local recurrence and was treated with PLA again.ConclusionUltrasound-guided PLA appears to be effective and safe for treating unifocal RPTCNs in selected patients who are ineligible for surgery, which is suitable for clinical application and promotion.https://www.frontiersin.org/articles/10.3389/fendo.2022.946966/fullthyroid cancerrecurrentpercutaneous thermal ablationlaserminimally invasive treatmentultrasound |
| spellingShingle | Liang Yong-ping Zhang Juan Jing-wu Li Huai-hua Qi Jing-ping Liu Yong-feng Zhao Wen-gang Liu Xing-hao Zhang Ping Zhou The value of ultrasound guided laser ablation in papillary thyroid recurrence carcinoma: A retrospective, single center study from China Frontiers in Endocrinology thyroid cancer recurrent percutaneous thermal ablation laser minimally invasive treatment ultrasound |
| title | The value of ultrasound guided laser ablation in papillary thyroid recurrence carcinoma: A retrospective, single center study from China |
| title_full | The value of ultrasound guided laser ablation in papillary thyroid recurrence carcinoma: A retrospective, single center study from China |
| title_fullStr | The value of ultrasound guided laser ablation in papillary thyroid recurrence carcinoma: A retrospective, single center study from China |
| title_full_unstemmed | The value of ultrasound guided laser ablation in papillary thyroid recurrence carcinoma: A retrospective, single center study from China |
| title_short | The value of ultrasound guided laser ablation in papillary thyroid recurrence carcinoma: A retrospective, single center study from China |
| title_sort | value of ultrasound guided laser ablation in papillary thyroid recurrence carcinoma a retrospective single center study from china |
| topic | thyroid cancer recurrent percutaneous thermal ablation laser minimally invasive treatment ultrasound |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.946966/full |
| work_keys_str_mv | AT liangyongping thevalueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT zhangjuan thevalueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT jingwuli thevalueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT huaihuaqi thevalueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT jingpingliu thevalueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT yongfengzhao thevalueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT wengangliu thevalueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT xinghaozhang thevalueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT pingzhou thevalueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT liangyongping valueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT zhangjuan valueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT jingwuli valueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT huaihuaqi valueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT jingpingliu valueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT yongfengzhao valueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT wengangliu valueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT xinghaozhang valueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina AT pingzhou valueofultrasoundguidedlaserablationinpapillarythyroidrecurrencecarcinomaaretrospectivesinglecenterstudyfromchina |